News

Everyone’s alopecia areata is different. Even though everyone who has it experiences hair loss, it may have many variations, including where, when, and how often you lose your hair. Alopecia ...
Hair fall, or hair loss, is a common dermatological problem that has several underlying causes. In some cases, it may be ...
Alopecia areata can arise in childhood, adolescence or adulthood, Dr. Lamb said. People who have the condition tend to lose hair in clumps, she said, causing round bald spots.
Alopecia areata is the condition affecting Jada Pinkett Smith, who found herself at the center of the Will Smith-Chris Rock conflict at the Oscars ceremony March 27. Dr. Brett King answers FAQs ...
The diagnosis was alopecia areata, which now considered an auto-immune response, ... Now he stood out even more because he was hairless; eyebrows, eyelids, all body hair was gone.
The stigma of having alopecia causes more depression and anxiety than the disease itself, new research has found.
Alopecia areata is the condition affecting Jada Pinkett Smith, who found herself at the center of the Will Smith-Chris Rock conflict at the Oscars ceremony March 27. Dr. Brett King answers FAQs ...
Jada Pinkett Smith in 2018 confirmed she was diagnosed with alopecia. There are multiple kinds of alopecia, including alopecia areata. Many people with conditions related to alopecia do see their ...
Alopecia areata can make both your professional and personal life hard to navigate. Research has found that as many as 1 in 6 people are uncomfortable having contact with someone who has hair ...
Alopecia areata, which is one type of alopecia, was thrust into the headlines last year when actor Will Smith confronted host Chris Rock at the Oscars following a joke Rock made about Smith's wife ...
New treatment for teens with alopecia. The FDA approved the once-daily pill called Litfulo, created by pharmaceutical giant Pfizer, for people 12 and up to treat severe alopecia areata, or at ...
Patients with severe alopecia areata were less likely to have complete improvement (0% vs 33.3%; P = .01) or any improvement (50% vs 84.9%; P = .02) compared with the nonsevere cohort.